Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date

Overview of attention for article published in Drug Design, Development and Therapy, July 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 30 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 19,324 followers.

RT @Endocrinology21: Profile of ipragliflozin for treating #type2diabetes | DDDT @DovePress https://t.co/iXBbvNOdDd #WednesdayMotivation…

Reply Repost Favourite

RT @Endocrinology21: Profile of ipragliflozin for treating #type2diabetes | DDDT @DovePress https://t.co/iXBbvNOdDd #WednesdayMotivation…

Reply Repost Favourite

Profile of ipragliflozin for treating #type2diabetes | DDDT @DovePress https://t.co/iXBbvNOdDd #WednesdayMotivation #Endocrinology #Diabetic #thyroid #adrennalyne #metabolism #MentalHealth #COVID19 #sepsis #diabetESP #diabeticretinopathy #clinicaltrials

Reply Repost Favourite